These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 4006736)
1. Prolonged elimination of piperacillin in a patient with renal and liver failure. Green L; Dick JD; Goldberger SP; Angelopulos CM Drug Intell Clin Pharm; 1985 Jun; 19(6):427-9. PubMed ID: 4006736 [TBL] [Abstract][Full Text] [Related]
2. The effect of hemodialysis on piperacillin pharmacokinetics. Heim-Duthoy KL; Halstenson CE; Abraham PA; Matzke GR Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):680-4. PubMed ID: 3818147 [TBL] [Abstract][Full Text] [Related]
3. In vivo inactivation of tobramycin by piperacillin. Uber WE; Brundage RC; White RL; Brundage DM; Bromley HR DICP; 1991 Apr; 25(4):357-9. PubMed ID: 1926903 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of piperacillin in hospitalized patients. Lau A; Lee M; Sharifi R Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):391-4. PubMed ID: 4044070 [TBL] [Abstract][Full Text] [Related]
5. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease. Halstenson CE; Wong MO; Herman CS; Heim-Duthoy KL; Teal MA; Affrime MB; Kelloway JH; Keane WF; Awni WM Antimicrob Agents Chemother; 1992 Sep; 36(9):1832-6. PubMed ID: 1416875 [TBL] [Abstract][Full Text] [Related]
6. Penetration of clindamycin, cefoxitin, and piperacillin into pancreatic juice in man. Brattström C; Malmborg AS; Tydén G Surgery; 1988 May; 103(5):563-7. PubMed ID: 3283981 [TBL] [Abstract][Full Text] [Related]
7. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. McCarty JM; Tilden SJ; Black P; Craft JC; Blumer J; Waring W; Halsey NA Pediatr Pulmonol; 1988; 4(4):201-4. PubMed ID: 3393383 [TBL] [Abstract][Full Text] [Related]
8. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. Arzuaga A; Maynar J; Gascón AR; Isla A; Corral E; Fonseca F; Sánchez-Izquierdo JA; Rello J; Canut A; Pedraz JL J Clin Pharmacol; 2005 Feb; 45(2):168-76. PubMed ID: 15647409 [TBL] [Abstract][Full Text] [Related]
9. The effect of piperacillin dose on elimination kinetics in renal impairment. Aronoff GR; Sloan RS; Brier ME; Luft FC Eur J Clin Pharmacol; 1983; 24(4):543-7. PubMed ID: 6222908 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531 [TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. De Schepper PJ; Tjandramaga TB; Mullie A; Verbesselt R; van Hecken A; Verberckmoes R; Verbist L J Antimicrob Chemother; 1982 Feb; 9 Suppl B():49-57. PubMed ID: 6460734 [No Abstract] [Full Text] [Related]
12. [Serum and urinary level of sodium piperacillin in patients with liver disease (author's transl)]. Kakiuchi S; Tagawa S; Watanabe K; Kosaka Y; Takezawa H Jpn J Antibiot; 1982 Jan; 35(1):212-21. PubMed ID: 6461777 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Derendorf H; Dalla Costa T Int J Clin Pharmacol Ther; 1996 Nov; 34(11):482-8. PubMed ID: 8937930 [TBL] [Abstract][Full Text] [Related]
14. Piperacillin therapy for Pseudomonas infections. Eron LJ; Goldenberg RI; Poretz DM; Park CH South Med J; 1983 Jul; 76(7):859-62. PubMed ID: 6223378 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of atracurium and its metabolites. Ward S; Weatherley BC Br J Anaesth; 1986; 58 Suppl 1():6S-10S. PubMed ID: 3754756 [TBL] [Abstract][Full Text] [Related]
16. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. Hoogkamp-Korstanje JA; van der Laag J J Antimicrob Chemother; 1983 Aug; 12(2):175-83. PubMed ID: 6619055 [TBL] [Abstract][Full Text] [Related]